147
Participants
Start Date
April 30, 2015
Primary Completion Date
December 31, 2019
Study Completion Date
April 30, 2020
BBI608
The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
BBI503
The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
Weill Cornell Medical College, New York
Virginia Cancer Specialists, PC, Fairfax
Indiana University Simon Cancer Center, Indianapolis
University of Chicago Medicine Comprehensive Cancer Center, Chicago
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology - Tyler, Tyler
Texas Oncology - Austin Midtown, Austin
Texas Oncology - Fort Worth 12th Ave, Fort Worth
Texas Oncology, P.A., San Antonio
Texas Oncology, P.A., San Antonio
Northwest Cancer Specialists, PC, Vancouver
Sumitomo Pharma America, Inc.
INDUSTRY